Direkt zum Inhalt
Merck

Fortfahren mit

SML0150

Tolcapon

≥98% (HPLC), Catechol-O-methyltransferase inhibitor, powder

Synonym(e):

3,4-Dihydroxy-4′-methyl-5-nitrobenzophenon, Ro 40-7592

zur Ansicht der Organisations- und Vertragspreise.

Größe auswählen

Ansicht ändern
Ihnen/SKUVerfügbarkeitPreis
10 mg
Warenkorb auf Verfügbarkeit prüfen
€ 76,60
50 mg
Warenkorb auf Verfügbarkeit prüfen
€ 297,00
€ 252,45

Über diesen Artikel

Empirische Formel (Hill-System):
C14H11NO5
CAS-Nummer:
Molekulargewicht:
273.24
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
Storage condition:
desiccated

€ 76,60


Warenkorb auf Verfügbarkeit prüfen

Sonderanfertigung anfragen
Technischer Dienst
Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.
Unterstützung erhalten


Produktname

Tolcapon, ≥98% (HPLC)

Quality Segment

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

yellow

solubility

DMSO: ≥15 mg/mL

originator

Roche

storage temp.

2-8°C

SMILES string

Cc1ccc(cc1)C(=O)c2cc(O)c(O)c(c2)[N+]([O-])=O

InChI

1S/C14H11NO5/c1-8-2-4-9(5-3-8)13(17)10-6-11(15(19)20)14(18)12(16)7-10/h2-7,16,18H,1H3

InChI key

MIQPIUSUKVNLNT-UHFFFAOYSA-N

Gene Information

human ... COMT(1312)

Application

Tolcapone may be used in COMT-mediated cell signaling studies.
Tolcapone has been used in methyltransferase assay in human embryonic kidney 293 cells.

Biochem/physiol Actions

Inhibition of catechol-O-methyltransferase by tolcapone increases the half-life and bioavailabilty of levodopa. It therefore is an effective adjunctive therapy in patients with Parkinson′s disease with motor response fluctuations.[1][2]
Orally active catechol-O-methyltransferase (COMT) inhibitor: inhibits both central and peripheral COMT.
Tolcapone is an orally active catechol-O-methyltransferase (COMT) inhibitor. It inhibits both central and peripheral COMT. Tolcapone crosses the blood-brain barrier, and has been used for L-DOPA adjunct therapy in the treatment of Parkinson′s Disease.

Features and Benefits

This compound was developed by Roche. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Ähnliche Artikel vergleichen

Vollständigen Vergleich anzeigen

Unterschiede anzeigen

1 of 1

Dieser Artikel
1670207R108T7080
Tolcapon United States Pharmacopeia (USP) Reference Standard

USP

1670207

Tolcapon

form

powder

form

-

form

solid

form

powder

assay

≥98% (HPLC)

assay

-

assay

-

assay

≥98% (HPLC)

Quality Level

100

Quality Level

-

Quality Level

100

Quality Level

100

storage temp.

2-8°C

storage temp.

-

storage temp.

2-8°C

storage temp.

2-8°C

storage condition

desiccated

storage condition

-

storage condition

protect from light

storage condition

-

solubility

DMSO: ≥15 mg/mL

solubility

-

solubility

H2O: slightly soluble <0.7 mg/mL, 45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: 1.0 mg/mL, ethanol: soluble

solubility

DMSO: >15 mg/mL


Still not finding the right product?

Explore all of our products under Tolcapon


pictograms

Environment

signalword

Warning

hcodes

Hazard Classifications

Aquatic Acute 1

Lagerklasse

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable



Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Dokumente section.

Wenn Sie Hilfe benötigen, wenden Sie sich bitte an Kundensupport

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen



Questions

Reviews

No rating value

Active Filters